Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving lenograstim vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization. Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes. 5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy. The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim.
Department of Oncology, Transplants and Advanced Technologies, University of Pisa, Pisa, Italy. orci@sssup.it
Enrico
E
Orciuolo
Gabriele
G
Buda
Emerenziana
E
Marturano
Elisa
E
Mauro
Giuseppe
G
Milone
Clotilde
C
Cangialosi
Nicola
N
Di Renzo
Domenico
D
Pastore
Giorgina
G
Specchia
Maria Rosaria
MR
De Paolis
Patrizio
P
Mazza
Giuseppe
G
Pietrantuono
Mario
M
Petrini
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000209:etiology / Q000517:prevention & control*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D003520:Cyclophosphamide; D000069585:Filgrastim